金城医药：子公司收到化学原料药CEP证书

Group 1 - The company announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the CEP certificate for Oseltamivir Phosphate from the European Medicines Agency [1] - The certificate is effective from July 25, 2025, and is numbered CEP2023-418 [1] - Oseltamivir Phosphate is a selective neuraminidase inhibitor used for the treatment of influenza A and B in adults and children aged one year and older, as well as for prevention in adults and adolescents aged 13 years and older [1] Group 2 - The global sales of the formulation for Oseltamivir Phosphate are projected to reach $1.017 billion in 2024, with a raw material consumption of 92.31 tons [1]